Familial breast/ovarian cancer and BRCA1/2 genetic screening: The role of immunohistochemistry as an additional method in the selection of patients

Journal of Histochemistry and Cytochemistry

Volumn 55, Issue 11, 2007, Pages 1105-1113

  Vaz, Fátima H ^a,b   Machado, Patrícia M ^a   Brandão, Rita D ^a   Laranjeira, Cátia T ^a   Eugénio, Joana S ^a   Fernandes, Aires H ^a   André, Saudade P ^a  

^a Instituto Portugues de Oncologia de Lisboa   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

BRCA1 2; Genetic screening; Hereditary breast cancer; Immunohistochemistry

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; DIAGNOSTIC ACCURACY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RECTUM CARCINOMA; WESTERN BLOTTING;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC SCREENING; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECTAL NEOPLASMS;

EID: 35548958612     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.7A7209.2007     Document Type: Article

References (40)

1. Al-Mulla F, Abdulrahman M, Varadharaj G, Akhter N, Anim JT (2005) BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem 53:621-629
2. American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
4. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316
5. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372
6. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK, et al. (1995) Aberrant subcellular localization of BRCA1 in breast cancer. Science 270:789-791
7. Coene E, Van Oosteveldt P, Willems K, van Emmelo J, De Potter CR (1997) BRCA1 is localized in cytoplasmic tube-like invaginations in the nucleus. Nat Genet 16:122-124
8. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA (1997) P53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638-639
9. den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7-12
10. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271
11. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403-410
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689
13. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, et al. (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485
14. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, et al. (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 7:2417-2425
15. Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 90:10325-10329
16. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, et al. (2006) Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 12:1494-1500
17. Henderson BR (2005) Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking. Bioessays 27:884-893
18. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, et al. (2005) Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2- associated tumors. J Clin Oncol 23:7503-7511
19. Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, Ohnishi T, et al. (1998) Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J Histochem Cytochem 46:397-403
20. Kashima K, Oite T, Aoki Y, Takakuwa K, Aida H, Nagata H, Sekine M, et al. (2000) Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res 91:399-409
21. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers, estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318
22. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735-742
23. Marmorstein LY, Ouchi T, Aaronson SA (1998) The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 95:13869-13874
24. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15-21
25. Palacios J, Honrado E, Osorio A, Diez O, Rivas C, Benitez J (2004) Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96:712-714
26. Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-148
27. Perez-Valles A, Martorell-Cebollada M, Nogueira-Vazquez E, Garcia-Garcia JA, Fuster-Diana E (2001) The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol 54: 476-480
28. Rodriguez JA, Au WW, Henderson BR (2004) Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res 293:14-21
29. Schofield AC, Payne S, Ross VG, Miller ID, Heys SD, Haites NE (2000) Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family. Breast 9:286-291
30. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88:265-275
31. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, et al. (1996) Location of BRCA1 in human breast and ovarian cancer cells. Science 272:123-126
32. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, et al. (2002) BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 20:994-999
33. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM (1999) Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci USA 96:13920-13925
34. Stormorken AT, Bowitz-Lothe IM, Noren T, Kure E, Aase S, Wijnen J, Apold J, et al. (2005) Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer. J Clin Oncol 23:4705-4712
35. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. J Natl Cancer Inst 94:1358-1365
36. Vaz FH, Machado PM, Brandão RD, Laranjeira CT, Eugénio JS, Fernandes AH, André SP (2007) Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem 55:1105-1113
37. Vega A, Campos B, Bressac-de-Paillerets B, Bond PM, Janin N, Douglas FS, Domenech M, et al. (2001) The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 17:520-521
38. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379-1388
39. Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713
40. Wilson CA, Payton MN, Elliot GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, et al. (1997) Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta 11b. Oncogene 14:1-16